Currently, the only designated MELK inhibitor is OTSSP167, an orally administered drug, which is under evaluation in Phase 1 studies on various tumor types (identifiers: NCT01910545, NCT02926690, NCT02768519, and NCT02795520; www.clinicaltrials.gov) [44,45,46]. This evidence concerns the gene MELK and neoplasm.